---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096191"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:44:12.196345+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q2 2024 loss from operations $22.6M; cash $97.5M, BDC-3042 advances to Cohort 6

## Summary
- Loss from operations of $22.6M for Q2 2024 vs $19.8M in Q2 2023; restructuring charges of $3.6M.
- Cash, cash equivalents and marketable securities of $97.5M as of June 30, 2024; runway through mid-2026.
- BDC-3042 Phase 1 advanced to Cohort 6; no dose-limiting toxicities in Cohort 5.
- BDC-4182 (claudin 18.2-targeting ISAC) abstract accepted at SITC 2024; IND-enabling activities ongoing.
- Collaboration revenue $1.3M; R&D expenses $15.4M; G&A expenses $4.9M.

## SEC filing metadata
- accession: 0000950170-24-096191
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000095017024096191/0000950170-24-096191-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000095017024096191/bolt-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096191
- JSON: https://secwatch.observer/filing/0000950170-24-096191.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096191.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.